Atgen Co. Ltd. | Balance Sheet

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Cash & Short Term Investments
722
4,008
26,095
47,591
25,485
Total Accounts Receivable
199
150
554
1,916
1,727
Inventories
1,215
1,717
3,115
4,139
4,155
Other Current Assets
231
137
201
1,063
715
Total Current Assets
2,366
6,011
29,965
54,708
32,082
Net Property, Plant & Equipment
1,151
1,300
1,444
2,389
3,130
Total Investments and Advances
264
304
648
7,727
14,957
Intangible Assets
45
35
61
62
1,091
Other Assets
-
-
250
2,625
2,785
Total Assets
3,826
7,651
32,369
67,512
54,044
ST Debt & Current Portion LT Debt
910
1,038
601
-
12,210
Accounts Payable
117
78
57
42
99
Other Current Liabilities
391
486
570
704
1,056
Total Current Liabilities
1,418
1,601
1,228
746
13,365
Long-Term Debt
3,820
7,827
1,424
24,238
-
Provision for Risks & Charges
419
618
959
1,213
-
Other Liabilities
23
-
-
638
730
Total Liabilities
5,679
10,046
3,611
26,835
14,094
Common Equity (Total)
1,853
2,396
28,757
40,676
39,950
Total Shareholders' Equity
1,853
2,396
28,757
40,676
39,950
Total Equity
1,853
2,396
28,757
40,676
39,950
Liabilities & Shareholders' Equity
3,826
7,651
32,369
67,512
54,044

About Atgen Co.

View Profile
Address
1st & 6th Floor, Health Care Park
Seongnam-si GY 13605
Korea, Republic Of
Employees -
Website http://www.nkvue.com
Updated 09/14/2018
ATGen Co., Ltd. engages in the development, manufacture, and sale of recombinant proteins and monoclonal antibodies. Its products include NK cells under NK Vue brand, recombinant proteins, and monoclonal antibodies. The company was founded on January 14, 2002 and is headquartered at Seongnam-si, South Korea.